SOUTH SAN FRANCISCO and SEATTLE, WA – Sept. 16, 2021 – Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, today announced the appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary. Leveraging over 20 years of legal and business experience, Sheehy will lead legal operations and sit on the company’s leadership team to help guide the strategic business decisions of the company.
“We are delighted to welcome Doug to the team as we continue this period of rapid growth as a company,” said Jeffrey Bluestone, Ph.D., Co-founder and CEO of Sonoma Biotherapeutics. “His decades of biopharma legal experience will bring valuable insights that will be critical as we work to advance our programs and pipeline.”
Sheehy is a senior biotechnology executive who has managed global legal and compliance operations for multiple companies. Prior to joining Sonoma, he served as General Counsel and Secretary for Aimmune Therapeutics, Inc., a publicly traded biopharmaceutical company that develops and commercializes treatments for potentially life-threatening food allergies. Sheehy previously served as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Codexis, Inc., and prior to that he served as Executive Director, Legal at CV Therapeutics, Inc. He started his career as a corporate and securities lawyer in Silicon Valley representing emerging growth companies and venture funds at Gunderson Dettmer. He received an A.B. in History from Dartmouth College and a J.D. from American University’s Washington College of Law.
“It’s an honor to join Sonoma Biotherapeutics as Chief Legal Officer and Secretary,” said Sheehy. “Having spent most of my career in this industry, I’m excited to work with a team that has such a proven track record, outstanding expertise, true passion, and dedication to advancing potentially curative cell therapies for patients. I look forward to contributing to the great work being done at Sonoma in autoimmune and inflammatory diseases.”
About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a South San Francisco and Seattle-based company leading the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases. Using genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease-modifying and curative therapies. For more information visit www.sonomabio.com and follow on Twitter and LinkedIn.